Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2013

View Archived Issues

Global Blood Therapeutics agent prevents sickling in sickle cell disease

Amgen reports topline results from phase III MENDEL-2 trial

to-BBB begins phase I study of 2B3-201 in healthy volunteers

Aquinox Pharmaceuticals begins phase II trial of AQX-1125 in COPD

Bioheart to begin AdipoCell study for dry macular degeneration

Vical begins phase I/II trial of a therapeutic HSV-2 vaccine

Endo Health Solutions to acquire NuPathe

Lilly joins Combinations Alliance to bring experimental molecules to clinical trials

CHRNA7 and CHRFAM7A gene expression linked to mental disorders

Stelis Biopharma and Pieris collaborate on Anticalin therapeutics in ophthalmology

ChemoCentryx develops CCR4 receptor antagonist for allergic diseases

Pfizer presents new Na(V)1.7 antagonist with promising activity in animal models of pain

Roche patents new Mdm2/p53 inhibitors for cancer

Novel antibodies for autoimmune disorders disclosed by German scientists

Sucampo and Takeda begin phase III program for lubiprostone in pediatric constipation

Takeda Pharmaceutical synthesizes novel PKR1 receptor antagonists

Onconova discontinues phase III study of rigosertib in pancreatic cancer

Researchers at Astex Pharmaceuticals present new FGFR inhibitors for cancer

FDA accepts supplemental BLA for Eylea in diabetic macular edema

Convergence Pharmaceuticals discloses new Na(V)1.7 blockers

GSK and Genmab receive FDA priority review for Arzerra BLA

BioLineRx begins phase I/II trial of BL-7010 in celiac disease

Preclinical and clinical studies evaluate ONO-4059 in B-cell malignancies, CLL

OMS-721 gains orphan status for complement-mediated thrombotic microangiopathies

Bayer HealthCare joins Structural Genomics Consortium for epigenetic research

FDA approves Anoro Ellipta for chronic obstructive pulmonary disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...